Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1946 1
1947 5
1948 1
1950 3
1951 5
1952 6
1953 4
1954 6
1955 4
1956 5
1957 9
1958 5
1959 6
1960 4
1961 5
1962 5
1963 3
1964 5
1965 4
1966 12
1967 8
1968 14
1969 11
1970 12
1971 16
1972 10
1973 13
1974 18
1975 22
1976 16
1977 19
1978 23
1979 22
1980 25
1981 25
1982 23
1983 30
1984 24
1985 31
1986 34
1987 32
1988 34
1989 32
1990 20
1991 36
1992 33
1993 31
1994 41
1995 46
1996 48
1997 39
1998 37
1999 60
2000 41
2001 64
2002 57
2003 54
2004 59
2005 90
2006 67
2007 93
2008 116
2009 99
2010 138
2011 142
2012 158
2013 173
2014 141
2015 150
2016 182
2017 162
2018 202
2019 209
2020 202
2021 241
2022 116
Text availability
Article attribute
Article type
Publication date

Search Results

3,589 results
Results by year
Filters applied: . Clear all
Page 1
Acquired Resistance to KRASG12C Inhibition in Cancer.
Awad MM, Liu S, Rybkin II, Arbour KC, Dilly J, Zhu VW, Johnson ML, Heist RS, Patil T, Riely GJ, Jacobson JO, Yang X, Persky NS, Root DE, Lowder KE, Feng H, Zhang SS, Haigis KM, Hung YP, Sholl LM, Wolpin BM, Wiese J, Christiansen J, Lee J, Schrock AB, Lim LP, Garg K, Li M, Engstrom LD, Waters L, Lawson JD, Olson P, Lito P, Ou SI, Christensen JG, Jänne PA, Aguirre AJ. Awad MM, et al. Among authors: christensen jg. N Engl J Med. 2021 Jun 24;384(25):2382-2393. doi: 10.1056/NEJMoa2105281. N Engl J Med. 2021. PMID: 34161704 Free PMC article.
Cytotoxic CD8+ T cells in cancer and cancer immunotherapy.
Raskov H, Orhan A, Christensen JP, Gögenur I. Raskov H, et al. Among authors: christensen jp. Br J Cancer. 2021 Jan;124(2):359-367. doi: 10.1038/s41416-020-01048-4. Epub 2020 Sep 15. Br J Cancer. 2021. PMID: 32929195 Free PMC article. Review.
The KRASG12C Inhibitor MRTX849 Reconditions the Tumor Immune Microenvironment and Sensitizes Tumors to Checkpoint Inhibitor Therapy.
Briere DM, Li S, Calinisan A, Sudhakar N, Aranda R, Hargis L, Peng DH, Deng J, Engstrom LD, Hallin J, Gatto S, Fernandez-Banet J, Pavlicek A, Wong KK, Christensen JG, Olson P. Briere DM, et al. Among authors: christensen jg. Mol Cancer Ther. 2021 Jun;20(6):975-985. doi: 10.1158/1535-7163.MCT-20-0462. Epub 2021 Mar 15. Mol Cancer Ther. 2021. PMID: 33722854
Genotype-phenotype correlations in SCN8A-related disorders reveal prognostic and therapeutic implications.
Johannesen KM, Liu Y, Koko M, Gjerulfsen CE, Sonnenberg L, Schubert J, Fenger CD, Eltokhi A, Rannap M, Koch NA, Lauxmann S, Krüger J, Kegele J, Canafoglia L, Franceschetti S, Mayer T, Rebstock J, Zacher P, Ruf S, Alber M, Sterbova K, Lassuthová P, Vlckova M, Lemke JR, Platzer K, Krey I, Heine C, Wieczorek D, Kroell-Seger J, Lund C, Klein KM, Billie Au PY, Rho JM, Ho AW, Masnada S, Veggiotti P, Giordano L, Accorsi P, Hoei-Hansen CE, Striano P, Zara F, Verhelst H, Verhoeven JS, van der Zwaag B, Harder AVE, Brilstra E, Pendziwiat M, Lebon S, Vaccarezza M, Minh Le N, Christensen J, Grønborg S, Scherer SW, Howe J, Fazeli W, Howell KB, Leventer R, Stutterd C, Walsh S, Gerard M, Gerard B, Matricardi S, Bonardi CM, Sartori S, Berger A, Hoffman-Zacharska D, Mastrangelo M, Darra F, Vøllo A, Motazacker MM, Lakeman P, Nizon M, Betzler C, Altuzarra C, Caume R, Roubertie A, Gélisse P, Marini C, Guerrini R, Bilan F, Tibussek D, Koch-Hogrebe M, Perry MS, Ichikawa S, Dadali E, Sharkov A, Mishina I, Abramov M, Kanivets I, Korostelev S, Kutsev S, Wain KE, Eisenhauer N, Wagner M, Savatt JM, Müller-Schlüter K, Bassan H, Borovikov A, Nassogne MC, Destrée A, Schoonjans AS, Meuwissen M, Buzatu M, Jansen A, Scalais E, Srivastava S, Tan WH, Olson HE, Loddenkemper T, Poduri A, Helbig KL, Helbig I, Fitzgerald MP, Goldberg EM, Roser T, Borggraefe I, Brünger T, May P, Lal D, Lederer D, Rubboli G, Heyne HO, Lesca G, Hedrich UBS, Benda J, Gardella E, Lerche H, Møller RS. Johannesen KM, et al. Among authors: christensen j. Brain. 2021 Aug 25:awab321. doi: 10.1093/brain/awab321. Online ahead of print. Brain. 2021. PMID: 34431999
Initial high-efficacy disease-modifying therapy in multiple sclerosis: A nationwide cohort study.
Buron MD, Chalmer TA, Sellebjerg F, Barzinji I, Christensen JR, Christensen MK, Hansen V, Illes Z, Jensen HB, Kant M, Papp V, Petersen T, Rasmussen PV, Schäfer J, Theódórsdóttir Á, Weglewski A, Sorensen PS, Magyari M. Buron MD, et al. Among authors: christensen jr. Neurology. 2020 Aug 25;95(8):e1041-e1051. doi: 10.1212/WNL.0000000000010135. Epub 2020 Jul 7. Neurology. 2020. PMID: 32636328
Five-Year Outcomes of the Partial Oral Treatment of Endocarditis (POET) Trial.
Pries-Heje MM, Wiingaard C, Ihlemann N, Gill SU, Bruun NE, Elming H, Povlsen JA, Madsen T, Jensen KT, Fursted K, Schultz M, Østergaard L, Christensen JJ, Christiansen U, Rosenvinge F, Helweg-Larsen J, Fosbøl EL, Køber L, Torp-Pedersen C, Tønder N, Moser C, Iversen K, Bundgaard H. Pries-Heje MM, et al. Among authors: christensen jj. N Engl J Med. 2022 Feb 10;386(6):601-602. doi: 10.1056/NEJMc2114046. N Engl J Med. 2022. PMID: 35139280 Clinical Trial. No abstract available.
The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma.
Horwitz S, O'Connor OA, Pro B, Trümper L, Iyer S, Advani R, Bartlett NL, Christensen JH, Morschhauser F, Domingo-Domenech E, Rossi G, Kim WS, Feldman T, Menne T, Belada D, Illés Á, Tobinai K, Tsukasaki K, Yeh SP, Shustov A, Hüttmann A, Savage KJ, Yuen S, Zinzani PL, Miao H, Bunn V, Fenton K, Fanale M, Puhlmann M, Illidge T. Horwitz S, et al. Among authors: christensen jh. Ann Oncol. 2022 Mar;33(3):288-298. doi: 10.1016/j.annonc.2021.12.002. Epub 2021 Dec 16. Ann Oncol. 2022. PMID: 34921960 Free article. Clinical Trial.
3,589 results